Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.

Høiby N.

BMC Med. 2011 Apr 4;9:32. doi: 10.1186/1741-7015-9-32. Review.

2.

Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Waters V, Ratjen F.

Cochrane Database Syst Rev. 2015 Mar 5;(3):CD009528. doi: 10.1002/14651858.CD009528.pub3. Review.

PMID:
25741986
3.

The cost effectiveness of dry powder antibiotics for the treatment of Pseudomonas aeruginosa in patients with cystic fibrosis.

Tappenden P, Harnan S, Uttley L, Mildred M, Walshaw M, Taylor C, Brownlee K.

Pharmacoeconomics. 2014 Feb;32(2):159-72. doi: 10.1007/s40273-013-0122-x.

PMID:
24338264
4.

Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.

Waters V, Ratjen F.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD009528. doi: 10.1002/14651858.CD009528.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;3:CD009528.

PMID:
23152277
5.

Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.

Nick JA, Moskowitz SM, Chmiel JF, Forssén AV, Kim SH, Saavedra MT, Saiman L, Taylor-Cousar JL, Nichols DP.

Ann Am Thorac Soc. 2014 Mar;11(3):342-50. doi: 10.1513/AnnalsATS.201310-352OC.

6.

Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.

Máiz L, Girón RM, Olveira C, Quintana E, Lamas A, Pastor D, Cantón R, Mensa J.

Expert Opin Pharmacother. 2013 Jun;14(9):1135-49. doi: 10.1517/14656566.2013.790366. Epub 2013 Apr 16. Review.

PMID:
23586963
7.

Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.

Ehsan Z, Clancy JP.

Future Microbiol. 2015;10(12):1901-12. doi: 10.2217/fmb.15.117. Epub 2015 Nov 17. Review.

8.
9.

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.

Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E; Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient.

Clin Microbiol Infect. 2005 Sep;11(9):690-703. Review.

10.

Changes in strategies for optimal antibacterial therapy in cystic fibrosis.

Ratjen F.

Int J Antimicrob Agents. 2001 Feb;17(2):93-6. Review.

PMID:
11165111
11.

Oral anti-pseudomonal antibiotics for cystic fibrosis.

Remmington T, Jahnke N, Harkensee C.

Cochrane Database Syst Rev. 2016 Jul 14;7:CD005405. doi: 10.1002/14651858.CD005405.pub4. Review.

PMID:
27412131
12.
13.

Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.

Greally P, Whitaker P, Peckham D.

Curr Med Res Opin. 2012 Jun;28(6):1059-67. doi: 10.1185/03007995.2012.674500. Epub 2012 May 10. Review.

PMID:
22401602
14.

Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.

McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB.

Am J Respir Crit Care Med. 2008 Nov 1;178(9):921-8. doi: 10.1164/rccm.200712-1804OC. Epub 2008 Jul 24.

15.

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.

Waters V, Ratjen F.

Cochrane Database Syst Rev. 2015 Nov 2;(11):CD006961. doi: 10.1002/14651858.CD006961.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Jun 19;6:CD006961.

PMID:
26522473
16.

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.

Langton Hewer SC, Smyth AR.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004197. doi: 10.1002/14651858.CD004197.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;11:CD004197.

PMID:
19821321
17.

The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Banerjee D, Stableforth D.

Drugs. 2000 Nov;60(5):1053-64. Review.

PMID:
11129122
18.

Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

Assael BM.

Expert Rev Anti Infect Ther. 2011 Nov;9(11):967-73. doi: 10.1586/eri.11.131. Review.

PMID:
22029514
19.

Oral anti-pseudomonal antibiotics for cystic fibrosis.

Remmington T, Jahnke N, Harkensee C.

Cochrane Database Syst Rev. 2013 Oct 29;(10):CD005405. doi: 10.1002/14651858.CD005405.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;7:CD005405.

PMID:
24170644
20.

Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa.

van Gennip M, Moser C, Christensen LD, Bjarnsholt T, Calum H, Jensen PØ, Christophersen L, Hougen HP, Ciofu O, Molin S, Givskov M, Høiby N.

J Antimicrob Chemother. 2009 Dec;64(6):1241-50. doi: 10.1093/jac/dkp352. Epub 2009 Oct 8.

PMID:
19815632

Supplemental Content

Support Center